Is HRT safe now? Here's what changed

How we got a black box warning in the first place

In 2002, the Women's Health Initiative (WHI), a large federal study, was stopped early after researchers reported that combined estrogen-progestin therapy raised the risk of breast cancer, heart disease, stroke, and blood clots. News coverage was alarming, and within a year hormone therapy use in the US dropped by more than half. The FDA added a black box warning, its strongest label alert, to all estrogen-containing products.

The problem: the average WHI participant was 63, more than a decade past the typical age of menopause, and most were started on an oral hormone formulation rarely prescribed today. The warning was written for that population and then applied to every woman on any form of hormone therapy, at any age.

What later research found: timing matters

Re-analyses of the WHI data over the following two decades, plus newer trials, converged on what researchers now call the timing hypothesis: the risk-benefit picture for hormone therapy depends heavily on how old a woman is, and how long it has been since menopause, when she starts. Women who start therapy under 60 or within 10 years of their final period tend to see a favorable balance of benefits (symptom relief, bone protection, some cardiovascular benefit) against risks. Starting a decade or more after menopause looks different, which is closer to what the original WHI cohort represented.

The FDA process that led to the 2025-2026 changes

The FDA convened a multidisciplinary expert panel on July 17, 2025, including members of The Menopause Society, to review the accumulated evidence on hormone therapy's risks and benefits. Several panelists said publicly that the existing warning overstated the risks, particularly for local vaginal estrogen.

On November 10, 2025, the FDA and HHS announced they would remove the boxed warning language tied to cardiovascular disease, breast cancer, and probable dementia from estrogen-containing menopause hormone therapy, and would work with manufacturers to rewrite labels with age-specific guidance. The endometrial cancer warning for estrogen-alone products was kept, since unopposed estrogen still raises that risk in women who have a uterus.

On February 12, 2026, the FDA approved the first batch of finalized label changes covering six products across all four hormone therapy categories: combined estrogen-progestogen, estrogen-alone, progestogen-alone, and topical vaginal estrogen. Twenty-nine drug companies have submitted proposed labeling updates, so more products are expected to follow.

What's actually changing on the ground

Prescribing is already responding. Among women aged 45-54, hormone therapy prescriptions rose about 26 percent between July 2025 and February 2026, on top of a longer upward trend since the mid-2010s. More doctors are treating perimenopausal symptoms as worth proactive treatment rather than something to tough out.

• The core menopause science has not changed - what changed is that the label now reflects who actually takes hormone therapy and when.
• This does not mean HRT is risk-free or right for everyone. Individual risk factors (personal or family history of certain cancers, blood clots, liver disease) still matter and still need a doctor's review.
• "Bioidentical" compounded hormones marketed outside FDA-approved products are not covered by these label changes and are not automatically safer.